失眠治疗市场 - 全球产业规模、份额、趋势、机会和预测，按类型、药物、配销通路、地区和竞争细分，2020-2030 年

2024 年全球失眠治疗市场价值为 31.2 亿美元，预计在预测期内将实现令人瞩目的成长，到 2030 年的复合年增长率为 5.48%。全球失眠治疗是一种多管齐下的方法，旨在解决世界范围内被称为失眠的普遍性睡眠障碍。失眠症的特征是难以入睡或难以维持睡眠，影响全球数百万人，影响他们的整体健康和生活品质。近年来，失眠症的治疗有了很大的进步，反映出人们越来越意识到失眠对身心健康的深远影响。全球失眠治疗的基本面向之一是开展教育和宣传活动，让公众和医疗保健提供者了解失眠的普遍性和后果。这包括传播有关睡眠卫生习惯、生活方式改变以及必要时寻求专业帮助的重要性的资讯。这些努力旨在减少与睡眠障碍相关的耻辱感并促进早期介入。

主要市场驱动因素

失眠盛行率上升

主要市场挑战

漏诊及误诊

主要市场趋势

远距医疗和远距医疗保健的兴起

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：全球失眠治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依类型（急性失眠、慢性失眠、发作性失眠、维持性失眠、儿童行为性失眠）
  • 依药物（右佐匹克隆、雷美替胺、扎来普隆、唑吡坦、艾司唑仑等）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按类型
  • 透过药物
  • 按配销通路
  • 按地区

第五章：亚太失眠治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型
  • 透过药物
  • 按配销通路
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲失眠治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第七章：北美失眠治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲失眠治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲失眠治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第十章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球失眠治疗市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Merck & Co
• Pfizer Inc.
• Abbott Laboratories
• Genentech Inc.
• LGM Pharma
• Sigma Aldrich Corp.
• Sanofi SA
• Takeda Pharmaceuticals Co. Ltd.
• Eisai Ltd.
• Idorsia Pharmaceuticals Apotex Corp

第 15 章：策略建议

第16章调查会社について・免责事项

Global Insomnia Treatment Market was valued at USD 3.12 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.48% through 2030. Global insomnia treatment is a multifaceted approach aimed at addressing the pervasive sleep disorder known as insomnia on a worldwide scale. Insomnia, characterized by difficulty falling asleep or staying asleep, affects millions of individuals across the globe, impacting their overall health and quality of life. The treatment of insomnia has evolved significantly in recent years, reflecting a growing awareness of its profound implications for physical and mental well-being. One of the fundamental aspects of global insomnia treatment involves education and awareness campaigns to inform the public and healthcare providers about the prevalence and consequences of insomnia. This includes disseminating information about sleep hygiene practices, lifestyle modifications, and the importance of seeking professional help when necessary. Such efforts aim to reduce the stigma associated with sleep disorders and promote early intervention.

Key Market Drivers

Rising Prevalence of Insomnia

The rising prevalence of insomnia has emerged as a significant catalyst for the growth of the global insomnia treatment industry. Insomnia, characterized by persistent difficulty falling asleep or staying asleep, has become increasingly common in today's fast-paced, digitally connected world. Stress, anxiety, lifestyle changes, and the prevalence of electronic devices that disrupt sleep patterns have all contributed to this escalating problem. According to data from the World Sleep Society, approximately 30% of adults experience short-term insomnia, while 10% suffer from chronic insomnia. This surge in insomnia cases has translated into a surge in demand for effective treatments. As more individuals experience sleep disturbances and their associated negative consequences on physical and mental health, they are turning to healthcare providers for solutions. This growing awareness of the detrimental impact of untreated insomnia has led to more individuals seeking medical attention and diagnosis, thereby driving up the number of reported cases and fueling the demand for insomnia treatment options. Also, the National Library of Medicine reports that approximately 30% of adults experience insomnia symptoms, emphasizing the urgent need for effective treatments. This growing demand has driven pharmaceutical companies and healthcare providers to develop innovative therapies and expand their offerings, fueling significant market growth.

Key Market Challenges

Underdiagnosis and Misdiagnosis

Insomnia, a prevalent sleep disorder characterized by difficulty falling or staying asleep, continues to plague millions across the globe. While the demand for effective treatments rises, the global insomnia treatment industry grapples with a significant barrier: underdiagnosis and misdiagnosis. This dual challenge not only hampers the growth of the treatment sector but also exacerbates the plight of those enduring sleepless nights.

For many, insomnia is dismissed as a mere consequence of a busy lifestyle, stress, or a transient phase. The normalization of sleepless nights has led many sufferers to overlook their symptoms, often hesitating to seek professional guidance. This pervasive attitude contributes to the vast underdiagnosis of insomnia, with numerous cases going unreported. As a result, a significant portion of the population remains deprived of appropriate treatment, enduring the physical, psychological, and socio-economic repercussions of untreated insomnia.

Key Market Trends

Rise in Telemedicine and Remote Healthcare

The rise in telemedicine and remote healthcare has emerged as a pivotal trend boosting the global insomnia treatment industry. Insomnia, a widespread sleep disorder affecting individuals worldwide, has historically presented challenges in terms of access to specialized care. However, the advent of telemedicine and remote healthcare solutions has ushered in a new era of accessibility and convenience for those in need of insomnia treatment.

The COVID-19 pandemic played a significant role in accelerating the adoption of telemedicine across various medical specialties, including sleep medicine. As social distancing measures and lockdowns disrupted traditional healthcare delivery, patients turned to virtual consultations with sleep specialists and therapists for their insomnia-related concerns. This shift in healthcare delivery eliminated geographical barriers, enabling individuals from diverse locations to access expert guidance and treatment options for their sleep disorders.

Key Market Players

• Merck & Co
• Pfizer Inc.
• Abbott Laboratories
• Genentech Inc.
• LGM Pharma
• Sigma Aldrich Corp.
• Sanofi S.A
• Takeda Pharmaceuticals Co. Ltd.
• Eisai Ltd.
• Idorsia Pharmaceuticals Apotex Corp

Report Scope:

In this report, the Global Insomnia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Insomnia Treatment Market, By Type:

• Acute Insomnia Chronic Insomnia
• Onset Insomnia
• Maintenance Insomnia
• Behavioral Insomnia of Childhood

Insomnia Treatment Market, By Drugs:

• Eszopiclone
• Ramelteon
• Zaleplon
• Zolpidem
• Estazolam
• Others

Insomnia Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Insomnia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Insomnia Treatment Market.

Available Customizations:

Global Insomnia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Insomnia Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Acute Insomnia Chronic Insomnia, Onset Insomnia, Maintenance Insomnia, Behavioral Insomnia of Childhood)
  • 4.2.2. By Drugs (Eszopiclone, Ramelteon, Zaleplon, Zolpidem, Estazolam, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drugs
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Insomnia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drugs
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Insomnia Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drugs
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Insomnia Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drugs
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Insomnia Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drugs
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Insomnia Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drugs
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Insomnia Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drugs
      • 5.3.5.2.3. By Distribution Channel

6. Europe Insomnia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drugs
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Insomnia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drugs
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Insomnia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drugs
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Insomnia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drugs
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Insomnia Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drugs
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Insomnia Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drugs
      • 6.3.5.2.3. By Distribution Channel

7. North America Insomnia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drugs
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Insomnia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drugs
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Insomnia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drugs
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Insomnia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drugs
      • 7.3.3.2.3. By Distribution Channel

8. South America Insomnia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drugs
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Insomnia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drugs
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Insomnia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drugs
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Insomnia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drugs
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Insomnia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drugs
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Insomnia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drugs
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Insomnia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drugs
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Insomnia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drugs
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. Egypt Insomnia Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Drugs
      • 9.3.4.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Insomnia Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Merck & Co
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Abbott Laboratories
• 14.4. Genentech Inc.
• 14.5. LGM Pharma
• 14.6. Sigma Aldrich Corp.
• 14.7. Sanofi S.A
• 14.8. Takeda Pharmaceuticals Co. Ltd.
• 14.9. Eisai Ltd.
• 14.10. Idorsia Pharmaceuticals Apotex Corp

15. Strategic Recommendations

16. About Us & Disclaimer